<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677244</url>
  </required_header>
  <id_info>
    <org_study_id>EUS-CTC-IPC 2019-056</org_study_id>
    <nct_id>NCT04677244</nct_id>
  </id_info>
  <brief_title>Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level</brief_title>
  <acronym>EUS-CTC</acronym>
  <official_title>Impact of Echo-endoscopy Biopsy on the Circulating Tumor Cell Level in the Portal System in Pancreatic Adenocarcinoma Management Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this work is to evaluate the impact of endoscopic procedures on the circulating&#xD;
      tumoral cells level in order to evaluate the potential effects of an endoscopic procedure in&#xD;
      the management of pancreatic tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 42 evaluable patients suspected of having pancreatic cancer and for&#xD;
      whom an echo-endoscopic biopsy (EUS-FNA) and/or biliary drainage is planned.&#xD;
&#xD;
      In these patients, a 6 ml blood sample will be taken from the portal vein before and after&#xD;
      the echo-endoscopic biopsy of the pancreatic mass to determine:&#xD;
&#xD;
        -  the level of circulating tumor cells (CTC) per milliliter of blood,&#xD;
&#xD;
        -  cytological characteristics of CTCs (isolated, clustered, giant, and clustered including&#xD;
           other cell types).&#xD;
&#xD;
      A peripheral blood sample will also be taken to evaluate peripheral CTC levels and&#xD;
      cytological characteristics before and after biopsy, as well as one month after biopsy.&#xD;
&#xD;
      Patients will be evaluated every 6 months as part of their follow-up to assess the&#xD;
      progression of their pathology and morbidity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective monocentric study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure impact</measure>
    <time_frame>5 minutes after procedure</time_frame>
    <description>Rate of patients with a CTC increase &gt; 4 cells/ml in the portal system after the endoscopic procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Cancer of Pancreas</condition>
  <arm_group>
    <arm_group_label>Portal vein blood sample</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample in portal vein</intervention_name>
    <description>A 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.</description>
    <arm_group_label>Portal vein blood sample</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 40-85 years old;&#xD;
&#xD;
          -  BMI&lt; 30 kg/m2;&#xD;
&#xD;
          -  Patients suspected of having pancreatic cancer for whom an ultrasound endoscopic&#xD;
             biopsy and/or biliary drainage is planned;&#xD;
&#xD;
          -  Affiliation to, or beneficiary of, a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Woman who is pregnant or likely to become pregnant (without effective contraception)&#xD;
             or breastfeeding ;&#xD;
&#xD;
          -  Person in an emergency situation, person of full age subject to a legal protection&#xD;
             measure, or unable to express consent;&#xD;
&#xD;
          -  Biliary drainage or attempt at prior biliary drainage outside the center ;&#xD;
&#xD;
          -  Preliminary oncological treatment for pancreatic pathology covered by the study;&#xD;
&#xD;
          -  Clinical and/or image-visible (CT/MRI) carcinosis ;&#xD;
&#xD;
          -  Ascites visible on imaging (CT/MRI) ;&#xD;
&#xD;
          -  Impossibility to undergo the medical follow-up of the trial for geographical, social&#xD;
             or psychological reasons;&#xD;
&#xD;
          -  Contraindications to an endoscopic procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice CAILLOL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paoli Calmettes Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

